GLP1R and type 2 diabetes mellitus: This was the first trial to assess outcomes for a once-weekly combination therapy of basal icodec and semaglutide in a large group of people with type 2 diabetes inadequately managed with GLP-1 RA therapy, with or without additional oral glucose-lowering medications.